MONARCH 1, a phase 2 study of abemaciclib, a CDK4 and CDK6 inhibitor, as a single agent, in patients with refractory HR+/HER2− metastatic breast cancer

PURPOSE: The phase 2 MONARCH 1 study was designed to evaluate the single-agent activity and adverse event (AE) profile of abemaciclib, a selective inhibitor of CDK4 and CDK6, in women with refractory hormone receptor positive (HR+), HER2− metastatic breast cancer (MBC). EXPERIMENTAL DESIGN: MONARCH...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Clin Cancer Res
Main Authors: Dickler, Maura N., Tolaney, Sara M., Rugo, Hope S., Cortés, Javier, Diéras, Véronique, Patt, Debra, Wildiers, Hans, Hudis, Clifford A., O’Shaughnessy, Joyce, Zamora, Esther, Yardley, Denise A., Frenzel, Martin, Koustenis, Andrew, Baselga, José
Format: Artigo
Jezik:Inglês
Izdano: 2017
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC5581697/
https://ncbi.nlm.nih.gov/pubmed/28533223
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-17-0754
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki